Streptavidin in antibody pretargeting. 3. Comparison of biotin binding and tissue localization of 1,2-cyclohexanedione and succinic anhydride modified recombinant streptavidin.
Recombinant streptavidin (rSAv) is of interest as a carrier of alpha-emitting radionuclides in pretargeting protocols for cancer therapy. Due to the inherently high kidney localization of rSAv, modification of this protein is required before it can be useful in pretargeting. Previous studies (Wilbur, D. S., Hamlin, D. K. et al. (1998) Bioconjugate Chem. 9, 322-330) have shown that succinylation of rSAv using succinic anhydride decreases the kidney localization appreciably. In continuing studies, the biotin binding characteristics and biodistribution in mice of rSAv modified by reaction with succinic anhydride (amine modification) or 1,2-cyclohexanedione (arginine modification) have been compared. Modification of rSAv was conducted using 5-50 mol equiv of succinic anhydride and 60-200 mol equiv of 1,2-cyclohexanedione. Most studies were conducted using rSAv modified with the highest quantities of reagents. Succinylation of rSAv did not alter binding with biotin derivatives, but a small increase in the biotin derivative dissociation rate was noted for arginine-modified rSAv. Amino acid analysis of 1,2-cyclohexanedione-treated rSAv indicated about 40% of the arginine residues, or an average of 1.6 residues per subunit, were modified, whereas none of the lysine residues were modified. IEF analyses showed that the pI of the arginine-modified rSAv was 5.3-6, whereas the pI for the succinylated rSAv was approximately 4. Electrospray mass spectral analyses indicated that one to three conjugates of 1,2-cyclohexanedione, and two to three conjugates of succinic anhydride, were obtained per subunit. Both modification reactions resulted in greatly decreasing the kidney localization of rSAv (normally 20-25% ID/g at 4, 24, and 48 h pi). However, the kidney concentration for the succinylated rSAv continued to decrease (5% ID/g to 1.5% ID/g) from 4 to 48 h pi, whereas the concentration (5% ID/g) remained constant over that period of time for the arginine-modified rSAv. In contrast to this, the liver concentration appeared to be slightly higher (3% ID/g vs 2% ID/g) at the later time points for the succinylated rSAv. When less than 50 mol equiv of succinic anhydride were employed in the modification of rSAv, a correlation between increasing kidney localization with decreasing equivalents reacted was observed. Although the differences in the two modified rSAv are not substantial, succinylated rSAv appears to have more favorable properties for pretargeting studies.
Wilbur
D Scott
DS
Department of Radiation Oncology, University of Washington, Seattle 98195, USA. dswilbur@u.washington.edu
Hamlin
Donald K
DK
Meyer
Damon L
DL
Mallett
Robert W
RW
Quinn
Janna
J
Vessella
Robert L
RL
Press
Oliver W
OW
D000818:Animals; D000912:Antibodies, Neoplasm / Q000276:immunology*; D001120:Arginine / Q000737:chemistry; D001710:Biotin / Q000031:analogs & derivatives / Q000378:metabolism*; D019921:Biotinylation / Q000379:methods; D002851:Chromatography, High Pressure Liquid; D003512:Cyclohexanones / Q000737:chemistry*; D007140:Immunoglobulin Fab Fragments / Q000737:chemistry / Q000276:immunology; D007457:Iodine Radioisotopes / Q000378:metabolism; D007668:Kidney / Q000378:metabolism*; D008297:Male; D013058:Mass Spectrometry; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009374:Neoplasms, Experimental / Q000276:immunology; D011994:Recombinant Proteins / Q000378:metabolism; D019809:Streptavidin / Q000031:analogs & derivatives / Q000378:metabolism*; D013386:Succinates / Q000737:chemistry*; D014018:Tissue Distribution
D000912:Antibodies, Neoplasm; D003512:Cyclohexanones; D007140:Immunoglobulin Fab Fragments; D007457:Iodine Radioisotopes; D011994:Recombinant Proteins; D013386:Succinates; D001710:Biotin; C018031:1,2-cyclohexanedione; D019809:Streptavidin; D001120:Arginine